New Zealand women with ovarian cancer finally have funded access to bevacizumab. Pharmac’s announcement yesterday comes ten years after the treatment was funded in Australia, and follows a long ...
On February 2, 2025, Shanghai Henlius Biotech, Inc. (“Henlius”) announced FDA acceptance of the Biologics License Application (BLA) for HLX11, a proposed biosimilar to Genentech’s PERJETA.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback